Inovio Pharmaceuticals (INO) Q4 2025 earnings summary

Executive summary

• BLA for INO-3107 accepted by FDA for review under the Accelerated Approval Program, with a PDUFA target date of October 30, 2026; FDA raised questions about eligibility for accelerated approval, and a meeting is pending.

• Commercial preparations for INO-3107 are well advanced, including resource optimization, partner selection, and launch strategies.

• Pipeline progress includes partnerships and collaborations for glioblastoma and rare disease programs, leveraging next-generation DNA medicine technologies.

• Published positive immunological and long-term clinical data for INO-3107, showing reduced need for surgery in RRP patients.

• Focus remains on advancing INO-3107 toward FDA approval and commercial launch.

Financial highlights

• Ended Q4 2025 with $58.5 million in cash, cash equivalents, and short-term investments, down from $94.1 million at end of 2024.

• Q4 2025 net income was $3.8 million, or $0.06 per share, driven by a $21.2 million non-cash gain on warrant liability adjustment.

• Full year 2025 net loss was $84.9 million, or $1.81 per share, improved from $107.3 million loss in 2024.

• Operating expenses decreased 23% year-over-year, from $112.6 million in 2024 to $86.9 million in 2025.

• No debt and projected cash runway into Q4 2026, with estimated Q1 2026 net cash burn of $22 million.

Outlook and guidance

• Cash runway projected into Q4 2026, not including potential capital raises.

• Priority is advancing INO-3107 toward commercialization and optimizing resources for regulatory milestones.

• Pipeline advancement for other candidates contingent on INO-3107 approval and available resources.

• Ongoing pipeline development with additional clinical candidate partnerships and next-generation DNA medicine innovation.